↓ Skip to main content

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

Overview of attention for article published in BMC Cancer, October 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
Published in
BMC Cancer, October 2013
DOI 10.1186/1471-2407-13-460
Pubmed ID
Authors

Pierre Fumoleau, Jose Manuel Trigo, Nicolas Isambert, Dorothée Sémiond, Sunil Gupta, Mario Campone

Abstract

Cabazitaxel is approved in patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing regimen. This study evaluated a weekly cabazitaxel dosing regimen. Primary objectives were to report dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD). Efficacy, safety and pharmacokinetics were secondary objectives.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
China 1 3%
Switzerland 1 3%
Unknown 27 93%

Demographic breakdown

Readers by professional status Count As %
Other 5 17%
Student > Bachelor 5 17%
Student > Postgraduate 5 17%
Researcher 5 17%
Student > Master 3 10%
Other 4 14%
Unknown 2 7%
Readers by discipline Count As %
Medicine and Dentistry 13 45%
Nursing and Health Professions 3 10%
Biochemistry, Genetics and Molecular Biology 2 7%
Computer Science 2 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 3 10%
Unknown 5 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2015.
All research outputs
#20,249,662
of 22,778,347 outputs
Outputs from BMC Cancer
#6,489
of 8,287 outputs
Outputs of similar age
#182,991
of 209,212 outputs
Outputs of similar age from BMC Cancer
#87
of 102 outputs
Altmetric has tracked 22,778,347 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,287 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,212 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.